at www.tipranks.com (Fri, 13-Nov 8:50 AM)
Inhibikase’s PAH Program Advances, Supporting Buy Rating and Unchanged $8 Price Target
at www.tipranks.com (Thu, 12-Nov 1:55 PM)
Analysts Offer Insights on NA Companies: Lucid Group (LCID) and Inhibikase Therapeutics (IKT)
at www.tipranks.com (Wed, 11-Nov 8:30 AM)
Inhibikase Therapeutics GAAP EPS of -$0.10 beats by $0.01
at seekingalpha.com (Tue, 10-Nov 5:03 PM)
